FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
Source: BioPharma Dive - Latest News
Tavneos’ original developer hid a study analysis and then altered data, the FDA alleged. Elsewhere, Erasca’s RAS drug was met with skepticism and Rocket Pharma sold a voucher.